Chronic myeloid leukaemia: The evolution of gene-targeted therapy

Medical Journal of Australia

Volumn 189, Issue 5, 2008, Pages 277-282

  Joske, David J L ^a  

^a SIR CHARLES GAIRDNER HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BCR ABL PROTEIN; BOSUTINIB; BUSULFAN; CYCLOPROPANECARBOXYLIC ACID [4 [4 (4 METHYL 1 PIPERAZINYL) 6 (5 METHYL 2H PYRAZOL 3 YLAMINO) 2 PYRIMIDINYLTHIO]PHENYL]AMIDE; CYTARABINE; DASATINIB; DORAMAPIMOD; HYDROXYUREA; IMATINIB; MK 4057; NILOTINIB; ONO 12380; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADVANCED CANCER; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; BONE MARROW BIOPSY; BONE MARROW SUPPRESSION; CANCER GENE THERAPY; CANCER INCIDENCE; CANCER RESISTANCE; CHROMOSOME TRANSLOCATION 22; CHROMOSOME TRANSLOCATION 9; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CYTOGENETICS; DIARRHEA; DISEASE FREE SURVIVAL; DRUG CHOICE; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ERUPTION; DRUG MECHANISM; DRUG MEGADOSE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DRY SKIN; FLU LIKE SYNDROME; HEART DISEASE; HEART FAILURE; HUMAN; LETHARGY; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; MUSCLE CRAMP; MUTATIONAL ANALYSIS; NAUSEA; OPTIMAL DRUG DOSE; ORBIT EDEMA; OVERALL SURVIVAL; PATIENT COMPLIANCE; PLEURA EFFUSION; POINT MUTATION; POLYMERASE CHAIN REACTION; PRURITUS; QT PROLONGATION; SIDE EFFECT; SURVIVAL RATE; TERATOGENICITY;

ANTINEOPLASTIC AGENTS; AUSTRALIA; DRUG APPROVAL; FUSION PROTEINS, BCR-ABL; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; PIPERAZINES; PYRIMIDINES; UNITED STATES;

EID: 53349100455     PISSN: 0025729X     EISSN: None     Source Type: Journal    
DOI: 10.5694/j.1326-5377.2008.tb02027.x     Document Type: Article

References (41)

1. Nowell PC, Hungerford DA. A minute chromosome in human granulocytic leukemia. Science 1960; 132: 1497.
2. Rowley JD. A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining [letter]. Nature 1973; 243: 290-293.
3. De Klein A, Geurts van Kessel A, Grosveld G, et al. A cellular oncogene is translocated to the Philadelphia chromosome in chronic myeloid leukemia. Nature 1982; 300: 290-293.
4. Daley GQ, Van Etten RA, Baltimore, D. Induction of chronic myelogenous leukemia in mice by the P2101bcr/abl gene of the Philadelphia chromosome. Science 1990; 247: 824-830.
5. The Italian Cooperative Study Group on Chronic Myeloid Leukemia. Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukaemia. N Engl J Med 1994; 330: 820-825.
6. Cross NC, Feng L, Chase A, et al. Competitive polymerase chain reaction to estimate the number of BCR-ABL transcripts of chronic myeloid leukaemia patients after bone marrow transplantation. Blood 1993; 82: 1929-1936.
7. Ross DM, Branford S, Moore S, Hughes T. Limited clinical value of regular bone marrow cytogenetic analysis in imatinib-treated chronic phase CML patients monitored by RQ-PCR for BCR-ABL. Leukemia 2006; 20: 664-670.
8. Vasella D, Slater R. Magic cancer bullet: how a tiny orange pill is rewriting medical history. New York: Harper Business, 2003.
9. Gangloff JM. Novartis to lobby health plans to cover Glivec. CMLSupport.com, 2001. http://www.cmlsupport.com/cmlglivecreport0301.htm (accessed Jul 2008).
10. Mayfield J. NEWCMLDRUG.COM [website]. http://www.newcmldrug.com/ (accessed Jul 2008).
11. O'Brien SG, Guilhot F, Larson RA, et, al; IRIS Investigators. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003; 348: 994-1004.
12. Druker BJ, Guilhot F, O'Brien SG, et al; IRIS Investigators. Five-year follow-up of patients receiving imatinib for chronic myelaid leukemia. N Engl J Med 2006; 355: 2408-2417.
13. Schiffer CA. BCR-ABL tyrosine kinase inhibitors for chronic myelogenous leukemia. N Engl J Med 2007; 357: 258-265.
14. Berman E, Nicolaides M, Maki RG, et al. Altered bone and mineral metabolism in patients receiving imatinib mesyiate. N Engl J Med 2006; 354: 2006-2013.
15. Pilot PR, Sablinska K, Owen S, Hatfield A. Epidemiological analysis of second primary malignancies in more than 9500 patients treated with imatinib. Leukemia 2006; 20: 148.
16. Medina J, Kantarjian H, Talpaz M, et al. Chromosomal abnormalities in Philadelphia chromosome-negative metaphases appearing during imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase. Cancer 2003; 98: 1905-1911.
17. Terre C, Eclache V, Rousselot F, et al. Report of 34 patients with clonal chromosomal abnormalities in Philadelphia-negative cells during imatinib treatment of Philadelphia-positive chronic myeloid leukemia. Leukemia 2004; 18: 1340-1346.
18. Kovitz C, Kantargian H, Garcia-Manero G, et al, Myelodysplastic syndromes and acute leukaemia developing after imatinib mesylate therapy for chronic myeloid leukaemia. Blood 2006; 108: 2811-2813.
19. Deininger MW, Cortes J, Paquette R, et al. The prognosis for patients with chronic myeloid leukemia who have clonal cytogenetic abnormalities in Philadelphia-chromosome negative cells. Cancer 2007; 110: 1509-1519.
20. Kerkela R, Grazette L, Yacobi R, et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med 2006; 12: 908-916.
21. Atallah E, Durand JB, Kantarjian H, Cortes J. Congestive heart failure is a rare event in patients receiving imatinib therapy. Blood 2007; 110: 1233-1237.
22. Rosti G. Case studies: pregnancy. Reproductive health and imatinib therapy [oral presentation]. CML Global Opinion Leader Summit. Practical Management of CML 2007: new options, new hope; 2007 Mar 2-4; Athens, Greece. http://www.cmlgolscme.com (accessed Jun 2008).
23. Grigg A, Hughes T. Role of allogeneic stem cell transplantation for adult chronic myeloid leukemia in the imatinib era. Biol Blood Marrow Transplant 2006; 12: 795-807.
24. Hughes T, Branford S, Reynolds J, et al. Higher dose imatinib (600 mg/ day) with selective intensification in newly diagnosed CML patients in chronic phase; cytogenetic response rates at 12 months are superior to IRIS [abstract]. Blood 2002; 104: 1001.
25. Cortes J, O'Brien S, Kantarjian H. Discontinuation of imatinib therapy after achieving a molecular response. Blood 2004; 104: 2204-2205.
26. Rousselot P, Huguet F, Rea D, et al. Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. Blood 2007; 109: 58-60.
27. Ault P, Kantarjian H, O'Brien S, et al. Pregnancy among patients with chronic myeloid leukemia treated with imatinib. J Clin Oncol 2006; 24: 1204-1208.
28. Sherbenou DW, Druker BJ. Applying the discovery of the Philadelphia chromosome. J Clin Invest 2007; 117: 2067-2074.
29. Gorre ME, Mohammed M, Ellwood K, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001; 293: 876-880.
30. Griswold IJ, MacPartlin M, Bumm T, et al. Kinase domain mutants of Bcr-Abl exhibit altered transformation potency, kinase activity, and substrate utilization, irrespective of sensitivity to imatinib. Mol Cell Biol 2006; 26: 6082-6093.
31. Warmuth M, Damoiseaux R, Liu Y, et al. SRC family kinases: potential targets for the treatment of human cancer and leukemia. Curr Pharm Des 2003; 9: 2043-2059.
32. Talpaz M, Shah NP, Kantarjian H, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 2006; 354: 2531-2541.
33. Kantarjian H, Giles F, Wunderie L, et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 2006; 354: 2542-2551.
34. Kantarjian H, Pasquini R, Hamerschlak N, et al. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid ieukaemia after failure of first-line imatinib: a randomized phase 2 trial. Blood 2007; 109: 5143-5150.
35. Giles FJ, Cortes J, Jones D, et al. MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation. Blood 2007; 109: 500-502.
36. O'Dwyer ME, Mauro MJ, Kurilik G, et al. The impact of clonal evolution on response to imatinib mesylate (ST1571) in accelerated phase CML. Blood 2002; 100: 1628-1633.
37. Sawyers CL, Hochhaus A, Feldman E, et al. Gleevec (imatinib mesylate) induces hematologic and cytogenetic responses in patients with chronic myeloid leukemia in myeloid blast crisis: results of a phase II study. Blood 2002; 99: 3530-3539.
38. Hughes T, Deininger M, Hochhaus A, et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 2006; 108: 28-37.
39. Baccarani M, Sagko G, Goldman J, et al. Evolving concepts in the management of chronic myeloid leukaemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2006; 108: 1809-1820.
40. Anstrom KJ, Reed SD, Allen AS, et al. Long-term survival estimates for imatinib versus interferon-α plus low-dose cytarabine for patients with newly diagnosed chronic-phase chronic myeloid leukaemia. Cancer 2004; 101: 2584-2592.
41. O'Hare T, Eide CA, Deininger MW. BCR-ABL kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia. Blood 2007; 110: 2242-2249.